GLAUKOS Corp GKOS
Sales up 32.3%, free cash flow up to -$22.5M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (39, from the latest 10-K and 10-Q)
- EPS (ttm)
- -2.95
- Sales (ttm)
- 690.3M
- Net income (ttm)
- -169.8M
- Sales growth
- +32.3%
- EPS growth
- -
- Sales Q/Q
- +58.0%
- Free cash flow
- 36.0M
- Gross margin
- 64.8%
- Oper. margin
- -25.5%
- Net margin
- -24.6%
- FCF margin
- 5.2%
- ROE
- -23.7%
- ROA
- -17.3%
- R&D / sales
- 29.7%
- Dividend
- -
- Debt/Eq
- -
- Curr. ratio
- 4.57
- Cash
- 162.3M
- Op. cash flow (ttm)
- 47.7M
- EBITDA
- -161.5M
- EBITDA margin
- -31.8%
- Quick ratio
- 4.07
- Interest cover
- -43.06
- FCF after stock pay
- -85.7M
- Goodwill / assets
- 7.5%
- Oper. margin low 5y
- -40.9%
- Stock pay / sales
- 12.5%
- Shares out.
- 59.2M
- Shares Y/Y
- +8.4%
- Book / share
- 12.12
- Cash / share
- 2.74
- Sales / share
- 11.66
- Asset turnover
- 0.70
- Inventory turns
- 1.76
- Days sales out.
- 78
- Sales 3Y CAGR
- +21.5%
- Sales 5Y CAGR
- +17.7%
- Employees
- 1,094
- Sales / employee
- 631K
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2016 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
- + Shareholders' equity $656.2M
- − Goodwill $66.7M
- − Other intangible assets $141.9M
- = Tangible book value $447.5M
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
GKOS against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| GKOS GLAUKOS Corp | $690.3M | +32.3% | 64.8% | -24.6% | -23.7% | 5.2% | - |
| RARE Ultragenyx Pharmaceutical Inc. | $730.0M | +20.2% | - | -71.8% | - | -60.5% | - |
| TMDX TransMedics Group, Inc. | $727.6M | +37.1% | 58.6% | 19.9% | 26.2% | 6.1% | - |
| TARS Tarsus Pharmaceuticals, Inc. | $682.2M | +147% | - | -102.9% | - | 4.8% | 0.70 |
| MIRM Mirum Pharmaceuticals, Inc. | $670.8M | +54.7% | - | -134.8% | - | -40.8% | - |
| UFPT UFP Technologies Inc | $649.5M | +19.5% | 28.9% | 11.8% | 15.8% | - | 0.20 |
Where the $507.4M of revenue came from
by product, year to Dec 31, 2025
- Glaucoma $421.1M · 83%
- Corneal Health $86.4M · 17%
From the segment tables in the 10-K XBRL.
Where the return on equity comes from
DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances
The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.
Profitability
-
Net margin below the peer median-24.6% vs 6.8%
-
Gross margin down over 5 years59.2% → 55.7%
-
Return on equity below 15%-23.7%
-
A profit in 2 of 10 years
Balance sheet
-
Interest covered less than 5 timesOperating income is -43.1× interest expense
-
Current assets cover current liabilitiesCurrent ratio 4.57
Cash and shareholders
-
Free cash flow positive in 3 of 10 years−$22.5M last year
-
Share count up over 5 years+28.5%
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
GKOS's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Revenue by product or service
year to Dec 31, 2025| Revenue | Share | vs year before | |
|---|---|---|---|
| Glaucoma | 421.1M | 83.0% | +38.8% |
| Corneal Health | 86.4M | 17.0% | +7.7% |
10-K 0001193125-26-061944, segment and revenue notes (XBRL).
Revenue by region
year to Dec 31, 2025| Revenue | Share | vs year before | |
|---|---|---|---|
| United States | 375.0M | 73.9% | +38.9% |
| International | 132.4M | 26.1% | +16.8% |
10-K 0001193125-26-061944, segment and revenue notes (XBRL).
Income statement
From EDGARBalance sheet
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | 6.5M | 24.5M | 29.8M | 62.4M | 96.6M | 100.7M | 119.5M | 93.5M | 169.6M | 90.8M |
| Receivables | 14.3M | 16.7M | 18.7M | 38.4M | 36.1M | 33.4M | 36.1M | 39.9M | 60.7M | 108.6M |
| Inventory | 6.8M | 11.2M | 13.3M | 42.6M | 15.8M | 23.0M | 37.8M | 42.0M | 57.7M | 63.6M |
| Current assets | 120.0M | 149.5M | 176.6M | 262.9M | 469.4M | 486.1M | 443.9M | 395.5M | 449.8M | 475.0M |
| Property & equipment | 7.6M | 11.8M | 19.2M | 22.1M | 24.0M | 69.0M | 94.4M | 103.2M | 97.9M | 113.3M |
| Goodwill | - | - | - | 66.1M | 66.1M | 66.1M | 66.1M | 66.1M | 66.1M | 66.7M |
| Other intangible assets | 6.6M | 3.1M | - | 382.6M | 357.7M | 332.8M | 307.9M | 283.0M | 263.4M | 141.9M |
| Total assets | 134.4M | 165.8M | 207.0M | 818.4M | 1.0B | 1.0B | 1.0B | 940.4M | 974.8M | 893.5M |
| Accounts payable | 3.0M | 6.2M | 6.3M | 5.8M | 4.4M | 7.3M | 14.4M | 13.4M | 13.0M | 24.6M |
| Current liabilities | 16.9M | 26.8M | 30.4M | 57.7M | 49.7M | 63.4M | 72.4M | 74.0M | 75.1M | 101.3M |
| Total liabilities | 17.1M | 27.6M | 33.1M | 145.1M | 338.1M | 462.5M | 472.4M | 478.6M | 207.8M | 237.3M |
| Shareholders' equity | 117.3M | 138.2M | 173.9M | 673.3M | 667.4M | 587.2M | 530.0M | 461.8M | 766.9M | 656.2M |
| Retained earnings | -192.1M | -192.2M | -205.1M | -189.7M | -310.1M | -365.2M | -464.4M | -599.1M | -745.4M | -933.1M |
Cash flow
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 12.3M | 26.1M | 18.9M | -369K | -23.0M | 24.7M | -33.1M | -57.8M | -61.3M | -14.8M |
| Capital spending | 6.3M | 6.3M | 10.3M | 4.7M | 6.9M | 47.8M | 30.3M | 20.2M | 6.3M | 7.7M |
| Free cash flow | 6.0M | 19.8M | 8.5M | -5.1M | -29.9M | -23.1M | -63.3M | -78.0M | -67.6M | -22.5M |
| Stock-based pay (added back) | 8.8M | 17.6M | 25.7M | 36.4M | 46.5M | 30.1M | 38.6M | 43.5M | 50.2M | 63.2M |
| Free cash flow after stock pay | -2.8M | 2.2M | -17.2M | -41.5M | -76.4M | -53.2M | -101.9M | -121.5M | -117.8M | -85.7M |
| Acquisitions | - | - | - | - | - | - | - | - | - | 12.4M |
| Debt raised | - | - | - | - | 287.5M | - | - | - | - | - |
| Investing cash flow | -26.1M | -12.4M | -26.4M | 43.4M | -205.1M | -58.2M | 44.8M | 14.1M | 47.8M | -77.6M |
| Financing cash flow | -1.6M | 4.7M | 21.6M | -9.6M | 262.5M | 39.3M | 6.3M | 15.0M | 91.5M | 11.9M |
Stock-based pay and leases
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 8.8M | 17.6M | 25.7M | 36.4M | 46.5M | 30.1M | 38.6M | 43.5M | 50.2M | 63.2M |
| Stock-based pay / revenue | 7.7% | 11.0% | 14.2% | 15.4% | 20.7% | 10.3% | 13.6% | 13.8% | 13.1% | 12.5% |
| Operating lease cash paid | - | - | - | 2.1M | 2.9M | 3.8M | 2.9M | 3.2M | 4.1M | 4.3M |
| Finance lease principal paid | - | - | - | - | - | 659K | 527K | 711K | 877K | 1.1M |
| Right-of-use assets | - | - | - | 15.7M | 20.0M | 28.1M | 25.8M | 27.1M | 30.3M | 31.5M |
| Operating lease liabilities | - | - | - | 16.6M | 21.9M | 30.7M | 29.3M | 31.7M | 35.3M | 37.1M |
| Finance lease liabilities | - | - | - | 58.4M | 60.7M | 72.7M | 72.2M | 71.5M | 70.6M | 69.5M |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GKOS/export.csv") into a cell.